Equities research analysts expect that Chromadex Corp (NASDAQ:CDXC) will post $10.80 million in sales for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Chromadex’s earnings, with the highest sales estimate coming in at $11.00 million and the lowest estimate coming in at $10.61 million. Chromadex posted sales of $7.80 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 38.5%. The company is expected to announce its next earnings results on Thursday, August 8th.
According to Zacks, analysts expect that Chromadex will report full year sales of $47.13 million for the current financial year, with estimates ranging from $45.22 million to $49.05 million. For the next year, analysts expect that the business will report sales of $83.71 million, with estimates ranging from $67.42 million to $100.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side analysts that that provide coverage for Chromadex.
Chromadex (NASDAQ:CDXC) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.04). Chromadex had a negative net margin of 94.78% and a negative return on equity of 108.84%. The company had revenue of $10.05 million during the quarter, compared to analyst estimates of $9.80 million.
Several equities analysts have issued reports on the stock. HC Wainwright set a $55.00 price objective on shares of Acer Therapeutics and gave the company a “buy” rating in a research note on Tuesday, May 28th. Zacks Investment Research cut shares of Haynes International from a “hold” rating to a “sell” rating in a report on Wednesday, May 8th. BidaskClub cut shares of Zebra Technologies from a “hold” rating to a “sell” rating in a report on Friday, May 24th. Finally, ValuEngine cut shares of Wave Life Sciences from a “strong-buy” rating to a “buy” rating in a report on Monday, March 25th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $6.00.
NASDAQ CDXC traded down $0.08 during trading hours on Friday, hitting $4.47. The company had a trading volume of 292,663 shares, compared to its average volume of 208,159. The company has a current ratio of 2.24, a quick ratio of 1.68 and a debt-to-equity ratio of 0.07. Chromadex has a 1-year low of $2.79 and a 1-year high of $5.00. The stock has a market cap of $252.62 million, a P/E ratio of -7.33 and a beta of 1.26. The firm has a 50 day moving average of $4.19.
Several large investors have recently made changes to their positions in the company. Northern Trust Corp raised its holdings in shares of Chromadex by 1.2% in the fourth quarter. Northern Trust Corp now owns 411,436 shares of the company’s stock valued at $1,412,000 after buying an additional 5,009 shares during the last quarter. BNP Paribas Arbitrage SA purchased a new position in Chromadex during the first quarter worth about $34,000. Woodard & Co. Asset Management Group Inc. ADV purchased a new position in Chromadex during the first quarter worth about $42,000. Rhumbline Advisers raised its holdings in Chromadex by 53.3% during the fourth quarter. Rhumbline Advisers now owns 48,511 shares of the company’s stock worth $166,000 after purchasing an additional 16,863 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in Chromadex by 5.3% during the fourth quarter. Geode Capital Management LLC now owns 346,723 shares of the company’s stock worth $1,189,000 after purchasing an additional 17,361 shares in the last quarter. 18.11% of the stock is owned by institutional investors and hedge funds.
ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function.
Read More: Exchange-Traded Funds (ETFs)
Get a free copy of the Zacks research report on Chromadex (CDXC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.